About Corindus Vascular Robotics (NYSEAMERICAN:CVRS)
Corindus Vascular Robotics, Inc. is engaged in robotic-assisted vascular interventions. The Company's CorPath System is a medical device that brings robotic-assisted precision to radial, coronary and peripheral procedures. The workstation allows the physician greater control and the freedom from wearing heavy lead protective equipment that causes musculoskeletal injuries. With the CorPath System it brings robotic precision to radial and complex interventional procedures to help optimize clinical outcomes and minimize the costs associated with complications of improper stent placement with manual procedures. It operates through the development, marketing and sales of robotic-assisted vascular interventions segment. The CorPath System enables the robotic-assisted control of coronary guidewires and balloon/stent devices from the safety of a radiation-protected, ergonomic interventional cockpit. The CorPath System consists of two components: a bedside unit and an interventional cockpit.
Industry, Sector and Symbol
Industry Advanced Medical Equipment & Technology
Trailing P/E Ratio-4.5
Forward P/E RatioN/A
Sales & Book Value
Price / SalesN/A
Price / CashN/A
Price / BookN/A
Return on Equity-110.93%
Return on Assets-88.11%
Corindus Vascular Robotics (NYSEAMERICAN:CVRS) Frequently Asked Questions
What is Corindus Vascular Robotics' stock symbol?
Corindus Vascular Robotics trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "CVRS."
How were Corindus Vascular Robotics' earnings last quarter?
Corindus Vascular Robotics Inc (NYSEAMERICAN:CVRS) issued its quarterly earnings results on Tuesday, November, 7th. The medical equipment provider reported ($0.04) EPS for the quarter, beating analysts' consensus estimates of ($0.05) by $0.01. The medical equipment provider had revenue of $2.43 million for the quarter, compared to analyst estimates of $3.60 million. Corindus Vascular Robotics had a negative return on equity of 110.93% and a negative net margin of 323.84%. View Corindus Vascular Robotics' Earnings History.
Where is Corindus Vascular Robotics' stock going? Where will Corindus Vascular Robotics' stock price be in 2018?
2 brokerages have issued 1 year price objectives for Corindus Vascular Robotics' stock. Their forecasts range from $3.00 to $3.00. On average, they expect Corindus Vascular Robotics' share price to reach $3.00 in the next year. View Analyst Ratings for Corindus Vascular Robotics.
Are investors shorting Corindus Vascular Robotics?
Corindus Vascular Robotics saw a decrease in short interest in the month of December. As of December 29th, there was short interest totalling 11,613,722 shares, a decrease of 2.8% from the December 15th total of 11,945,130 shares. Based on an average daily volume of 542,589 shares, the days-to-cover ratio is presently 21.4 days. Approximately 12.6% of the company's shares are sold short.
Who are some of Corindus Vascular Robotics' key competitors?
Some companies that are related to Corindus Vascular Robotics include Pulse Biosciences (PLSE), Pacific Biosciences of California (PACB), GenMark Diagnostics (GNMK), Cytosorbents (CTSO), Cogentix Medical (CGNT), Alliance HealthCare Services (AIQ), Harvard Bioscience (HBIO), Viveve Medical (VIVE), Fulgent Genetics (FLGT), IRIDEX (IRIX), Advanced Oncotherapy (AVO), Edap Tms (EDAP), Luna Innovations (LUNA), Presbia (LENS), Digirad (DRAD), Electromed (ELMD), Reshape Lifesciences (RSLS) and Neovasc Inc (US) (NVCN).
Who are Corindus Vascular Robotics' key executives?
Corindus Vascular Robotics' management team includes the folowing people:
- Jeffrey C. Lightcap, Independent Chairman of the Board (Age 57)
- Mark J. Toland, President, Chief Executive Officer, Director (Age 46)
- David W. Long, Chief Financial Officer, Senior Vice President, Treasurer, Secretary (Age 46)
- John K. Bakewell, Director (Age 55)
- Louis A Cannon M.D., Director
- Gerard Winkels, Director (Age 59)
- Hillel Bachrach, Independent Director (Age 70)
- Jeffrey Gold, Independent Director (Age 68)
Who owns Corindus Vascular Robotics stock?
Corindus Vascular Robotics' stock is owned by many different of retail and institutional investors. Top institutional investors include Schwab Charles Investment Management Inc. (0.11%). Company insiders that own Corindus Vascular Robotics stock include Healthcor Management, LP, Jeffrey Gold, Louis A Cannon and Philips Nv Koninklijke. View Institutional Ownership Trends for Corindus Vascular Robotics.
Who sold Corindus Vascular Robotics stock? Who is selling Corindus Vascular Robotics stock?
How do I buy Corindus Vascular Robotics stock?
Shares of Corindus Vascular Robotics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Corindus Vascular Robotics' stock price today?
One share of Corindus Vascular Robotics stock can currently be purchased for approximately $1.08.
How big of a company is Corindus Vascular Robotics?
Corindus Vascular Robotics has a market capitalization of $203.80 million.
How can I contact Corindus Vascular Robotics?
Corindus Vascular Robotics' mailing address is 309 Waverley Oaks Rd Ste 105, WALTHAM, MA 02452-8451, United States. The medical equipment provider can be reached via phone at +1-508-6533335.
MarketBeat Community Rating for Corindus Vascular Robotics (CVRS)MarketBeat's community ratings are surveys of what our community members think about Corindus Vascular Robotics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Corindus Vascular Robotics (NYSEAMERICAN:CVRS) Earnings History and Estimates Chart
Corindus Vascular Robotics (NYSEAMERICAN CVRS) Earnings History by Quarter
(Earnings results data provided by Zacks Investment Research)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|11/7/2017||Q3 2017||($0.05)||($0.04)||$3.60 million||$2.43 million||View||N/A|
|8/8/2017||Q2 2017||($0.05)||($0.04)||$3.10 million||$2.26 million||View||Listen|
|5/9/2017||Q1 2017||($0.05)||($0.07)||$1.59 million||$0.78 million||View||Listen|
|3/15/2017||Q4 2016||($0.07)||($0.08)||$0.73 million||$0.54 million||View||N/A|
|11/8/2016||Q316||($0.06)||($0.07)||$1.27 million||$0.69 million||View||Listen|
|3/8/2016||Q415||($0.05)||($0.06)||$0.62 million||$0.83 million||View||N/A|
|11/12/2015||Q315||($0.06)||($0.06)||$0.70 million||$0.21 million||View||Listen|
Corindus Vascular Robotics (NYSEAMERICAN:CVRS) Earnings Estimates
No earnings estimates for this company have been tracked by MarketBeat.com
Dividend History for Corindus Vascular Robotics (NYSEAMERICAN:CVRS)
No dividend announcements for this company have been tracked by MarketBeat.com
Corindus Vascular Robotics (NYSEAMERICAN CVRS) Insider Trading and Institutional Ownership History
Corindus Vascular Robotics (NYSEAMERICAN CVRS) Insider Trades by Quarter
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Shares Held After Transaction||Details|
|11/13/2017||Louis A Cannon||Director||Buy||23,801||$0.81||$19,278.81|| |
|3/22/2017||Louis A Cannon||Director||Buy||27,000||$1.30||$35,100.00|| |
|2/28/2017||Healthcor Management, L.P.||Major Shareholder||Buy||7,557,436||$0.66||$4,987,907.76|| |
|11/25/2016||Jeffrey Gold||Director||Buy||10,000||$0.76||$7,600.00||9,098|| |
Corindus Vascular Robotics (NYSEAMERICAN CVRS) News Headlines
|Corindus Vascular Robotics (CVRS) Lowered to "Hold" at Zacks Investment Research|
www.americanbankingnews.com - January 12 at 8:50 PM
|Corindus Vascular Robotics Inc (CVRS) Short Interest Update|
www.americanbankingnews.com - January 11 at 2:36 AM
|Detailed Research: Economic Perspectives on Athersys, Repros Therapeutics, GCP Applied Technologies, IDACORP, Mobile Mini, and Corindus Vascular Robotics — What Drives Growth in Today's Competitive Landscape|
finance.yahoo.com - January 4 at 8:53 AM
|Corindus to Participate with Mayo Clinic in Preclinical Study of Remote Control Robotics for Percutaneous Coronary ... - Business Wire (press release)|
www.businesswire.com - January 2 at 5:47 PM
|Corindus to Participate with Mayo Clinic in Preclinical Study of Remote Control Robotics for Percutaneous Coronary Interventions Remote Treatment Capabilities|
finance.yahoo.com - January 2 at 5:47 PM
|ETFs with exposure to Corindus Vascular Robotics, Inc. : December 28, 2017|
finance.yahoo.com - December 28 at 4:34 PM
|Corindus Announces First Commercial Installation of CorPath - Business Wire (press release)|
www.businesswire.com - December 15 at 6:34 PM
|Corindus Vascular Robotics (CVRS) Reports First Commercial Installation of CorPath GRX System Outside of US - StreetInsider.com|
www.streetinsider.com - December 15 at 6:34 PM
|Corindus Announces First Commercial Installation of CorPath® GRX System Outside of U.S.|
finance.yahoo.com - December 14 at 8:57 AM
|ETFs with exposure to Corindus Vascular Robotics, Inc. : December 11, 2017|
finance.yahoo.com - December 11 at 4:59 PM
|Corindus Partners with Houston Methodist DeBakey Heart & Vascular Center to Launch Premier Robotic Training Site for Physicians|
finance.yahoo.com - December 1 at 4:15 PM
|ETFs with exposure to Corindus Vascular Robotics, Inc. : November 30, 2017|
finance.yahoo.com - November 30 at 4:48 PM
|Short Interest in Corindus Vascular Robotics Inc (CVRS) Declines By 3.7%|
www.americanbankingnews.com - November 27 at 9:56 PM
|ETFs with exposure to Corindus Vascular Robotics, Inc. : November 20, 2017|
finance.yahoo.com - November 20 at 6:42 PM
Corindus Vascular Robotics (NYSEAMERICAN:CVRS) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Financials are not available for this stock.
Corindus Vascular Robotics (NYSEAMERICAN CVRS) Stock Chart for Saturday, January, 20, 2018